© Copyright Nostre Net
Neuroregeneration or nerve regeneration refers to the process of repair and regrowth of injured nerve tissues, cells, and cell products. Large number of cases of nervous system injuries combined with ongoing develpoments in neural tissue engineering is likely to warrant the need for neuroregeneration. The global nerve regeneration market report by Market Research Future (MRFR) covers trends, drivers, and challenges and illustrated in an enumerated method. Segments of the market, as well as its impacts on major regions of the world, are written in great detail.
Market Overview
The global nerve regeneration market share is projected to exhibit 11.34% CAGR during the forecast period (2017-2023). It can exceed the expected market valuation of USD 12,695.25 million by the end of 2023. Large number of nerve disorders, as well as developments in the treatments of such disorders, can drive the market growth exponentially till 2023. The large geriatric populace combined with the changing lifestyles of patients can trigger the afflictions and drive the demand for nerve regeneration procedures.
Investments in research and development are likely to boost the market demand significantly. For instance, Polyganics has established a new unit at the Zernike Campus, Netherlands for expanding their R&D unit. Surgeries to embed neurostimulation devices, as well as ongoing developments of a brain computer interface, can influence the market in the coming years. Advances in neuroimaging and neurostimulation which can provide relief to patients, can drive the market demand significantly.
But strict regulations, as well as exorbitant charges of surgeries, can hamper the market growth.
Competition Outlook
Boston Scientific Corporation, Medtronic, Integra LifeSciences, Abbott, Axogen Corporation, LivaNova PLC, Nuvectra Corporation, Stryker Corporation, Polyganics, and NeuroPace are key players in the global nerve regeneration market. Collaborations, product launches, and technological breakthroughs are certain strategies that can influence players in the market. For instance, NervGen Pharma recently decided to collaborate with Case Western Reserve University for rapidly bringing to market a new technology capable of treating patients with spinal cord injury. The use of proprietary agents termed as ISP can be used to impede the signals of protein tyrosine phosphatase (PTP), a key component that inhibits nerve regeneration.
Segmentation
The global tens for nerve regeneration market has been segmented on the basis of product, application, and end user.
Based on product, the market has been segregated into neurostimulation & neuromodulation devices and biomaterials. On the basis of neurostimulation and neuromodulation devices, the market has been divided into internal neurostimulation devices and external neurostimulation devices. Internal neurostimulation devices has been further segmented into vagus nerve stimulation, spinal cord stimulation, sacral nerve stimulation, deep brain stimulation, and gastric electrical stimulation. External neurostimulation devices cover transcutaneous electrical nerve stimulation and transcranial magnetic stimulation. Nerve conduits, nerve wraps, nerve protectors, and nerve connectors are segments encompassed within the biomaterials segment. Among them, the neurostimulation and neuromodulation devices segment was valued at USD 4,764.96 million in 2018. Large number of movement disorders and need for such tools for their treatment can drive the segment growth.
Major market applications include neurostimulation and neuromodulation surgeries, nerve grafting, stem cell therapy, direct nerve repair/neurorrhaphy, and others. Neurostimulation and neuromodulation surgeries have been further segmented into internal neurostimulation and neuromodulation surgeries, external neurostimulation, and neuromodulation surgeries. Nerve grafting encompasses autografts, allografts, and xenografts.
Primary end users of the global nerve regeneration market include hospitals & clinics, ambulatory surgery centers, and others.
Regional Analysis
MRFR segments the global nerve regeneration market on the basis of regions into Europe, the Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas held the maximum market share in 2017. The region receives considerable wherewithal for the continuous development of the healthcare sector. It can be lucrative for the global nerve regeneration market due to reimbursement policies which cover the costs of such treatments. Major companies based in this region who are investing considerably in the development of new products can drive the global market growth significantly.
Europe is expected to prove a windfall for the market due to substantial spending from governments for research and development in the healthcare sector. Large number of patients with nervous system disorders as well as disabled motor functions form the initial patient pool for such treatments. Launch of new machines for assisting in these surgical procedures as well as approval of CE for companies can drive the regional nerve regeneration market growth.
The APAC region can display a sharp demand for such products due to technological growth, massive populace, and increasing healthcare expenditure. India and China are displaying signs of unprecedented growth and triggering the demand for biomaterials which can drive growth during the forecast period. Collaborations with virtual reality solution providers for educating patients about the various neurological disorders and the latest treatment options available can bode well for the market. Recently, Wan Fang Hospital of Taipei decided to collaborate with the healthcare division of HTC which makes VIVE, a popular VR headset. It can be used to educate patients as well as doctors of the recent treatment options as well as the various nervous system disorders.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Market Overview
The precision in surgical procedures is developing due to better knowledge transfer and experience to handle a wide range of cases. Reports that assess the healthcare industry have been presented by Market Research Future, which creates reports on numerous industry verticals that examine the market progress and forecasts. The market is forecasted to earn revenues worth USD 1.1 billion while expanding at a CAGR of 8.9 % in the coming years.
The progress in the establishment of cutting-edge facilities has created a favorable impetus for the growth of the intraoperative neurophysiological monitoring market analysis. The factor of cost-effectiveness is also expected to considerably impact the advancement of the market in the impending period. Moreover, growing understanding related to the treatment of neurological ailments and better tools to operate in case of surgical intervention is expected to accelerate the growth of the intraoperative neurophysiological monitoring market in the forthcoming period.
The chief competitors in the intraoperative neurophysiological monitoring market are Accurate Monitoring LLC, Argos NeuroMonitoring LP, Computational Diagnostics Inc., Emotiv, Inomed Medizintechnik GmbH, Medsurant Holdings LLC, Cadwell Laboratories Inc., Natus Medical Incorporated, NuVasive, Neuro Alert, NuVasive, Neuromonitoring Technologies Inc., NeuroSentinel LLC, Procirca, Propep Surgical, SpecialtyCare and Sentient Medical Systems.
Segmental Analysis
The segmentation of the intraoperative imaging is carried out on the basis of type, procedure, methods, source, and region. Based on type, the intraoperative neurophysiological monitoring market is segmented into electromyography, electroencephalography, and evoked potentials. On the basis of procedure, the intraoperative neurophysiological monitoring market is segmented into otolaryngology surgery, spinal, neurovascular, orthopedic, and urology. The segmentation of the market based on the methods consists of non-invasive, invasive, and minimally invasive. Based on source, the intraoperative neurophysiological monitoring market comprises of outsourced, in-house, and telehealth. By region, the intraoperative neurophysiological monitoring market consists of Europe, Asia Pacific, North America, Middle East, and Africa.
Competitive Analysis
The surge in the market is credited to the presence of favorable market forces are expected to complement the development of the market. The positive reinforcement of the forces of demand and supply is expected to lift the market growth in the coming years. The synergies achieved in the manufacturing of the goods in the market are enhanced, leading to better growth prospects. The availability of productive resources is expected to further the progress of the market in the forecast period. The increased transaction level in the market is expected to spur an accelerated level of growth in the market. The conception of prodigious competitive advantages is likely to support the progress of the market. A considerable ascension in the number of promoters in the market is estimated to form a beneficial outlook for market growth in the projected period. The relaxation of the barriers to the entry of new players in the market is expected to encourage the expansion of the market in the impending years.
Detailed Regional Analysis
The assessment of the regions in the intraoperative neurophysiological monitoring market comprises of regions such as Europe, Asia Pacific, North America, Middle East, and Africa. The North American region is projected to head the IONM market with a noteworthy market share. The factors such as the increasing demand for the spinal and cranial procedures controlled by the rising number of patients is supporting the market growth of this region. The IONM market in the European region is responsible for the second largest stake in the market globally. The region is projected to reveal strong growth through the forecast period. The existence of the well-proliferated healthcare sector is leading to a growing number of advanced treatment facilities motivated by the increasing demand for better healthcare infrastructure and increasing healthcare expenditures. The Asia Pacific market for IONM appears as a lucrative market with the intensifying number of patients enduring spinal ailments and the ever-increasing population that is disposed towards a sedentary lifestyle. The growing funding from the government and private organizations are encouraging market growth by increasing the R&D activities in the region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
The Global Drugs Of Abuse Testing Market is expected to grow at a CAGR of 5.33% over the forecast period from 2019 to 2025, according to a new research report from Market Research Future (MRFR). A detailed profile of the global drug of abuse testing market is presented in the report, including an analysis of the key players operating in the market, the market’s leading drivers and restraints, and the leading segments holding a dominant share in the market. The past growth trajectory of the global drug of abuse testing market is also examined in detail in the report to enlighten readers as to the likeliest growth trajectory of the market in the forecast period. The global drugs of abuse testing services market is expected to rise to a value of more than USD 5 billion by the end of the forecast period in 2025, according to the report.
The growing use of illicit drugs all over the world and the growing awareness about drug of abuse testing are the major drivers for the global drugs of abuse testing market. Due to the growing number of youths becoming addicted to illegal substances, many governments around the world have come up with strong anti-drugs policies. Strict enforcement of drug monitoring policies is being practiced in most countries around the world. This has led to a growing demand for substance abuse treatment market. This is likely to remain the major driver for the global drug of abuse testing market over the forecast period due to the increasing government efforts to fight growing drug usage.
Technological refinement of small, portable drug of abuse testing devices is likely to be a major target for players in the global drug of abuse testing market over the forecast period. Parents are becoming increasingly concerned about illegal drug use by their wards, which has led to a growing demand for home-based testing for drugs. Drug of abuse testing equipment indicates whether drugs have been consumed within a specific timeframe, but they are not very good at revealing addiction patterns. This is likely to be a key restraint against the global drugs of abuse testing market over the forecast period.
Competitive Analysis:
Leading players in the global drug of abuse testing market include Quest Diagnostics, Thermo Fisher Scientific Inc., LabCorp, F. Hoffman-La Roche Ltd., Abbott Laboratories, Sonic Healthcare, Randox Laboratories, and Bio-Rad Laboratories Inc.
Segmentation:
The global drug of abuse testing market is segmented on the basis of test type and sample type.
By test type, the global drug of abuse testing market is segmented into laboratory drug testing and onsite screening tests. Onsite screening tests comprise the dominant segment due to the higher convenience and cost-effectiveness of onsite screening. The onsite screening tests segment held a dominant 71.62% share in the market in 2018.
On the basis of sample type, the drug of abuse testing market is segmented into urine, hair, saliva and others. Urine holds a majority share in the global drug of abuse testing market, as urine contains metabolites from several types of drugs. Saliva is the second most popular sample type in the drug of abuse testing market.
Regional Analysis:
The global drug of abuse testing market is segmented by region into North America, Europe, Asia Pacific, and rest of the world.
North America is the dominant revenue generator in the global drug of abuse testing market. The U.S. is the top consumer of drug of abuse testing devices and is likely to retain the position over the forecast period due to the strict enforcement of anti-drug legislation in the country. Awareness among parents about drug use among teenagers is also increasing, which is likely to be a key driver for the drug of abuse testing market in the U.S.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Actinic keratosis, simply put, is a scaly, rough patch on the skin which results from years of sun exposure. It is commonly found on the neck, scalp, forearms, back of the hands, ears, lips, or face. The size varies from a small inch to about a diameter, and when left untreated, such areas of the skin can turn into a serious type of skin cancer. Change in the color of the skin (brown, flesh-colored, or pink), hard wart-like surface, burning sensation and itching, and rough, patchy, scaly skin are some of its common symptoms.
The global actinic keratosis treatment market scope is predicted to touch USD 6,088.4 million at a 4.20% CAGR over the forecast period (2015-2024), states the new Market Research Future (MRFR) report.
No two cases will appear the same, yet is likely to share similar features such as sandpaper texture, crusty patches, raised patches, and red scales. Though anyone can develop actinic keratosis, but those with fair skin, particularly blonde or red hair, green or blue eyes, or skin that easily burns or freckles have a higher risk of experiencing porokeratosis treatment.
Various factors are propelling the Actinic Keratosis Treatment growth. These factors, according to the new MRFR report, include its increasing prevalence, increasing acceptance of therapeutic procedures that are minimally invasive, growing geriatric population, and the presence of suitable medical coverage. Additional factors pushing market growth include the availability of suitable medical attention and environmental factors such as excessive sun exposure and ozone depletion.
Key Players
Leading players profiled in the actinic keratosis treatment market report include Cipher Pharmaceuticals Inc., Valeant Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Alma Lasers, Stanford Chemicals, 3M, Leo Pharma, BioLineRx, and Biofrontera AG. Various strategies have been adopted by key players to create a foothold in the market such as research and development activities, joint ventures/partnership, mergers and acquisitions, collaborations, expansions, product launches, and development.
Market Segmentation
The MRFR report provides a complete segmental analysis of the actinic keratosis treatment market report on the basis of end user, procedure, and medication.
Based on medication, the actinic keratosis treatment market is segmented into diclofenac gel, ingenol mebutate gel, imiquimod cream, fluorouracil cream, and others.
Based on procedure, the actinic keratosis treatment market is segmented into chemical peels, laser, photodynamic therapy, cryotherapy, and others. Of these, the cryotherapy segment will have the largest share in the market over the forecast period. This is a common treatment used for actinic keratosis.
Based on end user, the actinic keratosis treatment is segmented into ambulatory surgical centers, dermatology clinics, and hospitals and oncology centers. Of these, the hospitals and oncology segment will dominate the market over the forecast period.
Regional Analysis
By region, the actinic keratosis treatment market report covers the latest trends and growth opportunities across the Asia Pacific, Europe, the Americas, and the Middle East and Africa. Of these, the Americas will spearhead the market over the forecast period. Factors aiding growth in the region include easy availability of advanced treatment methods such as monotherapy and combination therapy and increasing efforts taken on cancer research in the region.
The actinic keratosis treatment market in the APAC region is predicted to have significant growth over the forecast period. Factors aiding growth in the region include growing government support for medical tourism, rising healthcare spending, rising literacy rates, rapidly growing healthcare infrastructure, and rising disposable income. India, Japan, and China are the key contributors in this region.
The actinic keratosis treatment market in Europe will have a favorable growth over the forecast period while the Middle East and Africa will experience sluggish growth.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
It is estimated that the global preimplantation genetic testing market is expected to register a CAGR of 10.2% during the forecast period of 2019 to 2025, with a market value of USD 375.8 million in 2018.
Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes. Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.
The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age. This leads to the growth of the genetic testing for rare diseases during the forecast period. According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5, which is 3% less, this shows the reduction in the rate of fertility.
An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing market growth.
Key Players
Some of the major players in the global preimplantation genetic testing market are Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science Ltd
Segmentation
The presymptomatic genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.
The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS). Hundred different genetic conditions can be tested with Preimplantation Genetic Diagnosis (PGD) which enables the couple to have a baby with no genetic defect thus the segment is expected to hold the largest market share owing to rising awareness population and healthcare experts. Preimplantation Genetic Screening (PGS) segment is also anticipated to grow profitably to increase healthy pregnancy.
By type, embryo testing segment is expected to show favorable growth as the threat of chromosomal abnormalities increases. By product and service, the reagents and consumables segment anticipated to hold the largest market share as there is continuous declination infertility of female due to increasing usage of reagents for the diagnosis. By technology, the next-generation sequencing segment, and comparative genomic hybridization also expected to hold large share as its cost is reduced and its capability to detect mosaicism. The market by end user has been segmented into maternity centers & fertility clinics
hospitals, diagnostic labs and research laboratories & academic institutes. Based on region, the global preimplantation genetic testing market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The global preimplantation genetic testing market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European global preimplantation genetic testing market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The global preimplantation genetic testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The IPF treatment market in the Middle East & Africa has been divided into the Middle East and Africa.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
The global ultrasound devices market is expected to exhibit a strong 8.1% CAGR over the forecast period, rising to a valuation of USD 10.37 billion by 2023, according to a new report from Market Research Future (MRFR). The report elaborates on the major drivers and restraints for the global ultrasound devices market in detail by analyzing their impact on the market’s trajectory over the forecast period.
The growing demand for ultrasound devices for diagnostic purposes is likely to be the major driver for the global ultrasound devices market trends over the forecast period. Ultrasound devices work by sending out high-frequency sound waves that provide a picture of the targeted area based on the response of various bodily tissues to the sound waves. Since different tissues react differently to the same sound waves, the technique has become popular in the healthcare sector. The lack of invasion in the use of critical care ultrasound equipment has also become a key plus point for the market due to the growing obsession with minimally invasive and noninvasive medical procedures. Therapeutic applications of ultrasound include targeting a specific patch of tissue for stimulation or removal by bombarding it with high-frequency sound waves. This application is also likely to remain a key factor for the global ultrasound devices market’s growth over the forecast period.
The growing demand for more advanced ultrasound devices in the gynecology sector is likely to be a major driver for the global ultrasound devices market over the forecast period. The development of 3D and 4D ultrasound imaging has allowed for the diagnosis of congenital defects clearly and earlier in the pregnancy, which has made the procedures widely popular in the healthcare sector around the world. 4D imaging also allows live action viewing of the fetus, which allows physicians to detect more abnormalities. This is likely to be a major driver for the global ultrasound devices market over the forecast period.
Competitive Analysis:
Leading players in the global ultrasound devices market include Siemens AG, GE, Hitachi Ltd., Shimadzu Corporation, Analogic Corporation, Mindray Medical International Ltd., Toshiba Corporation, Samsung Electronics Co. Ltd., and Koninklijke Philips NV.
Leading players in the global ultrasound devices market are likely to focus on bringing about steady technological innovation and updation in their products in the coming years, as developing more modern products has become a key selling point in the industry. The rising threat of web-based intrusions is also likely to make companies focus more on technological updation. In March 2019, security specialist Check Point Software Technologies said in a report that ultrasound devices running on older operating systems such as Windows 2000 were virtually defenseless against modern hackers, which could result in the hackers gaining access to confidential hospital information and making exorbitant ransom demands on the hospital. Eliminating this threat is likely to be top of the agenda for the leading players in the global ultrasound devices market over the forecast period.
Segmentation Analysis:
By portability, cart/trolley-based devices accounted for the largest market share in 2017 due to its utilization in acute and emergency care settings. The segment is likely to register strong CAGR during the forecast period expected to hold significant market share during the forecast period. Handheld/compact ultrasound devices accounted for the second largest share due to the rising adoption of these by healthcare professionals.
By display, color devices accounted for a largest market share in 2017 compared to its counterpart, black/white ultrasound devices. The former can touch a size of USD 7,509.12 million by 2026, while the latter is likely to show prominent growth by the end of the forecast period.
By application, radiology/general imaging is likely to register highest CAGR during the assessment and likely to dominate the market by 2026. It accounted for the largest market share in 2017 due to its vast medical applications. The rising geriatric populace and incidence of various cancers can spur the segment growth. On the other hand, cardiology is also showing significant growth by 2026.
By technology, diagnostic accounted for the largest market share in 2017 due to the use of 2D ultrasound in women’s health. It is likely to show CAGR over the assessment period and hold significant market share by 2026 due to the continuous advances in imaging and reimbursement schemes for these procedures. On the flip side, therapeutic ultrasound is expected to hold second position by 2026.
By end-user, hospitals and diagnostic & surgical centers dominated the ultrasound devices market in 2017 due to emergence of various hospital chains and rising number of minimally invasive diagnostic procedures by doctors. The segment can grow with strong CAGR and expected to hold first position in the market. Ambulatory care centers can exhibit the highest CAGR of 3.61% during the forecast period thanks to the facilities providing same-day care diagnostic and surgical procedures.
Regional Analysis:
The Americas is likely to be the major regional market for ultrasound devices over the forecast period due to the widespread adoption of advanced ultrasound technology in the region and the growing demand for advanced diagnostic modalities and devices. Europe is also likely to remain a major regional market for ultrasound devices over the forecast period due to the growing healthcare expenditure in the region. Asia Pacific is expected to exhibit the fastest growth over the forecast period due to the growing demand for advanced medical facilities and devices and the increasing investment in hospitals and medical technology.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Market Overview
Market Research Future (MRFR) says that the global gene expression analysis market could hold the value of USD 3.250 million by 2023. The market could also achieve a CAGR of 9.1% during the forecast period (2018-2023).
Growth Boosters and Key Restraints
Personalized medicine, with its ability to affect diagnostic and treatment decisions for every patient, has brought an evolution in modern medicine. Diagnosis, treatment, as well as lifestyle interventions, have now become progressively personalized to every patient genetics, family history along with other factors.
Technologies have made it easier for healthcare professionals to track every patient’s health information and offer personalized care. Personalized medicine has gained immense traction as a result of the boost in the number of genetic disorders. Additionally, the mounting awareness about this form of treatment will drive the market in the near future. The rising technological advancement including molecular services and NGS are uplifting the demand for gene expression services. This factor will ensure the success of the gene expression analysis market report during the evaluation period.
The downside could be the high cost of instruments, hindering the market growth in the review period. But the development of genomic databases, surge in government funding towards genomics, and increasing personalized medicine are projected to elevate the market position in the subsequent years.
Rising Investments in Gene Expression Analysis Researches
With single cell gene expression, genetic modifications recorded in animals like mice has given way to advancements in drug discover as well as development, clinical diagnostics and biotechnology, among others. Companies along with research institutes are working on projects based on gene expression analysis. These projects are seeing massive success backed by high investments as the demand for nucleic acid analysis, gene cloning & analysis, and other related microbiological methods is rising.
Leading Vendors
Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC COMPANY, Pacific Biosciences of California, Inc., Illumina, Inc., Genotypic Technology Pvt Ltd, Danaher, QIAGEN, Oxford Gene Technology, Thermo Fisher Scientific, BGI, PerkinElmer Inc., Macrogen Inc., Eurofins Scientific, are some of the companies currently leading the worldwide gene expression analysis market.
Market Segmentation
The global market for epigenetics drugs has been segmented on the basis of product, services, application, and end-user.
The market, product-wise, include consumables and instruments.
Depending on consumables, the market covers reagents and DNA chips.
Instruments-based segments in the market are polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others.
The services mentioned in the report are gene expression profiling services, sequencing services, bioinformatics solutions, and others.
Gene expression analysis finds applications in drug discovery, diagnosis, research, and others.
The end-users highlighted in the report are pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others.
Regional Outlook
The primary markets for gene expression analysis are Europe, Asia Pacific, Middle East & Africa and the Americas.
During the forecast period, the Americas could very well reach the top position in the global gene expression analysis market, estimates MRFR. The highly-established infrastructure, huge expenditure, and increasing research and development activities in the region play a big role in this growth. The market also gets a boost from the large number of established players based in the region. Case in point is GE Healthcare, which alone generated revenue of USD 19.1 Billion in 2017.
Standing at the second spot, Europe is now an established region in the global gene expression analysis market. The regional market gains from the numerous government initiatives taken in research and development associated with gene expression analysis. Europe is also inundated with esteemed companies such as F. Hoffmann-La Roche Ltd. To illustrate, F. Hoffmann-La Roche, in February 2018, had received an approval from the U.S. Food and Drug Administration (FDA) for its multiplex Factor V and Factor II assessment which could be used on Cobas 4800 systems. This system is known for achieving real-time PCR analysis for high volume labs.
Asia Pacific could expect the fastest growth in the worldwide market. The rising number of global partnerships for the expansion of the region’s healthcare sector, government focus on cancer as well as life science research and internal manufacturing of the sequencing systems favors the regional market. Other factors promoting market growth could be the massive R&D investments and the booming bioresearch centers. On top of this, the surge in the number of research activities in agriculture and the growing approval of gene expression tests add to the market’s strength.
Middle East and Africa could project weak growth in the coming years on account of substandard healthcare amenities and low fund investments associated with research and development activities.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Opioids are medications prescribed by doctors and physicians to treat various levels of pain. These can include acute pain and chronic non-cancer pain. They are also known as painkillers and used to block pain signals from the brain. Market Research Future (MRFR) has stressed the advantages of the intake of opioids as well as the efforts by manufacturers to address various issues concerning the drugs.
Growth Drivers
The global opioids market share is slated to attain a valuation of USD 29,535.80 million by 2023, as per the latest report by MRFR. Pain management of various chronic diseases remain the primary driver of the market. According to the National Institute of Drug Abuse, nearly 200 million prescriptions were dispensed by U.S. pharmacies in 2017. The large number of prescriptions is an indicator for the large scope of the market.
Favorable reimbursement schemes for covering the costs of opioids in palliative care can work in favor of the market. Large number of patients diagnosed with various cancers can drive the market demand for opioids till 2023. Rise in surgical procedures and road accidents are other factors which can contribute to market demand due to the need for pain relievers. All of these factors are predicted to push the market to exhibit a CAGR of 7.12% during the forecast period.
Establishment of new guidelines to curb the intake of opioids and reduce the addiction rates are expecteFuture Perspective, Emerging Technologies And Analysis By Forecast to disrupt the market in a positive manner. For instance, the sale of over-the-counter drugs containing opioids is restricted, while stringent measures are undertaken regarding prescriptions given by doctors. New policies by government-supported insurance companies such as Medicare are limiting the dispensation rate of opioids to 7 days.
But misuse of opioid induced respiratory depression treatment and adverse effects of the drugs which lead to addiction threaten the market growth.
Segments In-Detail:
MRFR has segmented the global opioids market by product, application, and end-user.
Based on the product, the market is segmented into immediate release/short-acting opioid and extended release/long-acting opioid. Extended release comprises hydromorphone, oxycodone, morphine, oxymorphone, and others. The extended release segment had accounted for USD 12,750.91 million in 2017. This segment can expand in the coming years due to rising prevalence of chronic diseases.
By application, it is segmented into diarrhea suppression, deaddiction, cough suppression, pain relief, anesthesia, and others. The pain relief segment is expected to be the dominant application of the opioids market due to rise in pain management therapies. Moreover, new guidelines for selling prescription drugs coupled with rise in palliative and end-of-life care can boost segment growth. This in turn can drive the market demand exponentially.
By end-user, the market caters to academic research institutes, hospitals & clinics, and pharmacies.
Regional Analysis:
MRFR’s report takes a deep look into major regions which include the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).
The Americas is predicted to be dominant in the global market due to holding the largest market share due to awareness among patients and the high intake of the drugs for pain alleviation. On the other hand, Europe is expected to showcase prolific growth due to rise in palliative care centers and strict regulations regarding opioid usage.
Market Synopsis:
Market Research Future (MRFR)’s new analysis projects that the global healthcare chatbots market is set to witness healthy growth in the forthcoming years. The integration of Artificial Intelligence (AI) in the healthcare sector has paved the way for the adoption of chatbots. Additionally, healthcare chatbots are poised to handle complex tasks such as personal monitoring, appointment booking, etc. in an efficient manner and maximize the productivity of the organization. This, in turn, is expected to propel the expansion of the chatbots vs conversational ai.
The inclination towards cost cutting without compromising on the quality of services has accelerated the adoption of the technology in the healthcare sector. Additionally, the large-scale penetration of IT services has further catalyzed the growth of the top health chatbots market. The trend is projected to perpetuate over the next couple of years.
The compatibility of chatbots with mobile platforms has accelerated revenue creation for the players of the healthcare chatbots market application. The exponential demand for smartphones is prognosticated to drive the growth of the market significantly in the coming years.
Market Segmentation:
By component, the healthcare chatbots market has been segmented into software and services.
By deployment model, the global healthcare chatbots market is segmented into on-premise model and cloud-based model.
By application, the healthcare chatbots market has been segmented into symptom checking & medication assistance, and appointment scheduling & medical guidance.
By end user, the global healthcare chatbots market is segmented into patients, healthcare providers, insurance companies and others.
Regional Analysis:
By region, the global healthcare chatbots market has been segmented into Europe, North America, Asia Pacific, and the Rest of the World. North America is set to witness significant growth over the next couple of years. The factors responsible for favoring the growth of the regional market include rapid technological advancements, increasing adoption of artificial intelligence, consolidation of key players and presence of developed healthcare sector.
Europe is another important growth pocket of the global healthcare chatbot market. Rising healthcare expenditure coupled with increased research and development activities are set to aid the healthcare chatbots market proliferation in the region.
Asia Pacific is a highly lucrative market globally and is expected to remain so in the foreseeable future. The growth trajectory of the healthcare chatbots market in the region is guided by increasing investment in modernization of healthcare facilities and rising demand for advanced technologies in the healthcare sector. Meanwhile, the Middle East & Africa is set to exhibit little growth. The growth of the region is driven by Middle Eastern countries with developed healthcare sectors, while, the economically backward African regions remain impediments to market expansion.
Competitive Dashboard:
Some of the key players profiled in the report are Babylon Healthcare Service Limited (U.K.), PACT Care BV (Netherlands), Sensely, Inc. (U.S.), Buoy Health, Inc. (U.S.), Your.MD (U.K.), Infermedica (Poland), GYANT.Com, Inc. (U.S.), Ada Digital Health Ltd. (Germany), HealthTap, Inc. (U.S.), Baidu, Inc. (China), and Woebot Labs, Inc. (U.S.).
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Market Synopsis
Market Research Future (MRFR) asserts that the global autoimmune disease diagnostics market is likely to register a CAGR of 7.6% during the forecast period (2018-2023) owing to an increased prevalence of autoimmune diseases worldwide. Autoimmune disease is considered as a disorder where the body’s own immune system starts to attack the healthy cells in place of the foreign particles and disease-causing agents. Auto antibody test, antinuclear antibody test, complete blood count, C-reactive protein, and erythrocyte sedimentation rate are some of the tests performed for diagnosis of the autoimmune disease.
Market Potential and Pitfalls
The global autoimmune disease diagnostics market share is likely to experience an upsurge owing to the increased prevalence of autoimmune disease, surging awareness regarding autoimmune diseases, and rising expenditure on healthcare. The increasing spending on R&D activities coupled with the aggressive strategies adopted by the top market players like new product launches along with mergers and acquisitions are anticipated to contribute to the market growth across the globe. For instance, Abbott acquired Alere Inc. in October 2017 for USD 5300 million. The deal will enable Abbott to gain control over USD 7000 million diagnostics sales of Alere Inc. and also strengthen their position in the global market.
The increasing occurrences of several diseases like rheumatoid arthritis and Hashimoto’s thyroiditis are likely to influence the market across the globe. Several initiatives taken by the government regarding global spread of autoimmune disease are further contributing to its growth. As per the American Autoimmune Related Diseases Association, approximately 50 million people from America are suffering from autoimmune related disorders. Such factors are likely to create immense opportunities to the growth of the market.
Competitive Dashboard
The prominent players operating in the global autoimmune disease diagnostics market comprises bioMérieux SA, Siemens Healthcare Private Limited, Beckman Coulter Inc., Bio-rad Laboratories, EUROIMMUN AG, AstraZeneca, Inova Diagnostics Inc., F. Hoffmann-la Roche, Thermo Fisher Scientific, Myriad Genetics Inc., Hemagen Diagnostics Inc., and Trinity Biotech Plc.
Global Autoimmune Disease Diagnostics Market: Segmental Analysis
The global autoimmune disease diagnostics market has been segmented on the basis of test type, disease type, and end-user.
By mode of disease type, the global autoimmune disease diagnostics market has been segmented into systemic autoimmune disease, and localized autoimmune disease. Among these, the localized autoimmune disease segment is likely to gain prominence owing to the presence of large procedure volume and higher patient awareness level.
By mode of test type, the global autoimmune disease diagnostics market has been segmented into enzyme-linked immunosorbent assay (ELISA), western blotting, dot blot, double immune diffusion, line blot, counter immune-electrophoresis, multiplex immunoassay, immunofluorescence assays (IFA), agglutination, and others.
By mode of end-users, the global autoimmune disease diagnostics market has been segmented into diagnostics centers, hospitals, research laboratories, and others.
Regional Insights
Geographically, the autoimmune disease diagnostics market span across regions namely, Europe, America, Asia-Pacific, and the Middle East & Africa.
Considering the global scenario, the American region is predicted to command the maximum share in the global market. The region is likely to retain its pole position owing to the surging prevalence of autoimmune diseases like rheumatoid arthritis. Moreover, the rising financial support by the private organizations and governments coupled with the adoption of high advanced technology in this region is anticipated to contribute to the growth of the market. As per a report published by the Arthritis Foundation in 2017, around 91 million Americans were suffering from arthritis, 300000 of them were children.
The European region is predicted to occupy the second spot in the global market owing to the increased automation in the laboratories, rising healthcare industry, and strategies implemented by the top market players like mergers & acquisitions and product launches.
The Asia Pacific region is likely to expand at the fastest growth rate during the assessment period. The growth can be ascribed to the inflating population, rising private-public partnerships for the improvement of the healthcare sector, and surging prevalence of autoimmune disorders in this region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America